BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor

Core Insights - BBO-11818 is a selective, orally bioavailable non-covalent inhibitor targeting KRAS in both ON and OFF states, showing strong activity in KRAS mutant preclinical models and significant tumor growth inhibition across multiple tumor types [1][6] - The drug has demonstrated enhanced efficacy in combination with other anti-tumor agents, including BBO-10203, a selective RAS:PI3Kα breaker [1][3] - Preliminary clinical data from the Phase 1 KONQUER-101 trial indicate encouraging anti-tumor activities and differentiated safety, with further data expected in the second half of 2026 [1][4] Company Overview - BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, aiming to improve outcomes for patients with cancers driven by prevalent oncogenes [7] - The company is advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies [7] Drug Development - BBO-11818 has shown potent activity against multiple clinically relevant KRAS mutants, including KRAS and KRAS, with over 500-fold selectivity for KRAS over other RAS isoforms [3] - The drug's design aims to prevent resistance driven by secondary activating KRAS mutations, which can limit the efficacy of allele-specific inhibitors [3] - Monotherapy studies have demonstrated robust anti-tumor activity across various in vitro and in vivo models of KRAS mutant solid tumors, including colorectal, pancreatic, and lung cancers [3] Collaboration and Research - The discovery and development of BBO-11818 resulted from collaboration between BBOT, the RAS Initiative at Frederick National Laboratory, and Lawrence Livermore National Laboratory [5] - The publication detailing BBO-11818's discovery was featured in the peer-reviewed journal Cancer Discovery, highlighting its therapeutic potential for patients with KRAS mutant cancers [1][2]